Type I Interferons in Autoimmunity : Implications in Clinical Phenotypes and Treatment Response
Copyright © 2023 by the Journal of Rheumatology..
Type I interferon (IFN-I) is thought to play a role in many systemic autoimmune diseases. IFN-I pathway activation is associated with pathogenic features, including the presence of autoantibodies and clinical phenotypes such as more severe disease with increased disease activity and damage. We will review the role and potential drivers of IFN-I dysregulation in 5 prototypic autoimmune diseases: systemic lupus erythematosus, dermatomyositis, rheumatoid arthritis, primary Sjögren syndrome, and systemic sclerosis. We will also discuss current therapeutic strategies that directly or indirectly target the IFN-I system.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
The Journal of rheumatology - 50(2023), 9 vom: 01. Sept., Seite 1103-1113 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Londe, Ana Carolina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.09.2023 Date Revised 28.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3899/jrheum.2022-0827 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35900668X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35900668X | ||
| 003 | DE-627 | ||
| 005 | 20231226075939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3899/jrheum.2022-0827 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM35900668X | ||
| 035 | |a (NLM)37399470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Londe, Ana Carolina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Type I Interferons in Autoimmunity |b Implications in Clinical Phenotypes and Treatment Response |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.09.2023 | ||
| 500 | |a Date Revised 28.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the Journal of Rheumatology. | ||
| 520 | |a Type I interferon (IFN-I) is thought to play a role in many systemic autoimmune diseases. IFN-I pathway activation is associated with pathogenic features, including the presence of autoantibodies and clinical phenotypes such as more severe disease with increased disease activity and damage. We will review the role and potential drivers of IFN-I dysregulation in 5 prototypic autoimmune diseases: systemic lupus erythematosus, dermatomyositis, rheumatoid arthritis, primary Sjögren syndrome, and systemic sclerosis. We will also discuss current therapeutic strategies that directly or indirectly target the IFN-I system | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Sjögren syndrome | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a interferons | |
| 650 | 4 | |a myositis | |
| 650 | 4 | |a systemic lupus erythematosus | |
| 650 | 7 | |a Interferon Type I |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 700 | 1 | |a Fernandez-Ruiz, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Julio, Paulo Rogério |e verfasserin |4 aut | |
| 700 | 1 | |a Appenzeller, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Niewold, Timothy B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of rheumatology |d 1983 |g 50(2023), 9 vom: 01. Sept., Seite 1103-1113 |w (DE-627)NLM000019593 |x 1499-2752 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:1103-1113 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3899/jrheum.2022-0827 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 9 |b 01 |c 09 |h 1103-1113 | ||